ANIK Anika Therapeutics, Inc.
Debt Financing ·
Anika Therapeutics signed a fifth amendment to its Bank of America revolving credit line, now maturing July 10, 2031. The filing names no amount drawn, and the line carries a first-priority lien on most of the company's assets.
Anika completed the sale of its former subsidiary Parcus Medical to Medacta Americas Manufacturing on March 7, 2025 for $4,500,000 in cash at closing, still subject to post-closing adjustments. The 2023 annual report shows a $62.2 million impairment on the Parcus and Arthrosurface intangibles.
The deal closed on March 7, 2025 for an undisclosed amount, paid in cash at closing. Anika will now focus on hyaluronic acid pain products and regenerative solutions.
Anika Therapeutics, Inc., founded in 1992, is a company that uses proprietary hyaluronic acid, or HA, technology to develop products for osteoarthritis pain management and regenerative solutions in early intervention orthopedics. Its OA Pain Management portfolio includes Monovisc and Orthovisc, single- and multi-injection HA viscosupplements indicated for pain relief from OA, and Cingal, a non-opioid, single-injection product that combines cross-linked HA with a fast-acting steroid. Cingal is CE marked and has been sold outside the United States directly in over 50 countries, but it is not currently approved for commercial use in the United States. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. The Regenerative Solutions portfolio includes the Integrity Implant System, an HA-based scaffold for rotator cuff and other tendon repairs. Anika submitted a premarket approval application for Hyalofast on October 31, 2025, and received an FDA letter in January 2026 identifying deficiencies that the company is addressing. The company sold Arthrosurface and Parcus Medical to focus on these two portfolios.
| Product or program | What it is | Stage |
|---|---|---|
| Monovisc | Single-injection HA viscosupplement for osteoarthritis pain, labeled for the knee in the U.S. | Marketed |
| Orthovisc | Multi-injection HA viscosupplement for osteoarthritis pain | Marketed |
| Cingal | Non-opioid single-injection HA with a fast-acting steroid for OA pain | CE marked; not currently approved in the United States |
| Hyalofast | Regenerative Solutions product for which a U.S. PMA was submitted | PMA submitted October 31, 2025; FDA deficiency letter January 2026 |
| Integrity Implant System | HA-based scaffold for rotator cuff and other tendon repairs |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $112.8 million | $119.9 million |
| Research and development | $25.8 million | $25.5 million |
| Net income (loss) | -$10.9 million | -$56.4 million |
| Cash from operations | $11.2 million | $5.4 million |
| Cash and equivalents | $57.5 million | $55.6 million |
| Short-term investments | $23.7 million | $23.6 million |
Anika Therapeutics, Inc. trades under the ticker ANIK on NASDAQ.
Anika Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Anika Therapeutics, Inc. is 898437. Its filings are on SEC EDGAR.
13,382,966 shares as of 2026-07-24, per the cover page of its 10-Q filed 2026-07-29.
Our directory records Anika Therapeutics, Inc. under United States.
Our directory classifies Anika Therapeutics, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Anika Therapeutics, Inc. is US0352551081.
aibio.space lists Anika Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Anika Therapeutics, Inc., founded in 1992, is a company that uses proprietary hyaluronic acid, or HA, technology to develop products for osteoarthritis pain management and regenerative solutions in early intervention orthopedics. Its OA Pain Management portfolio includes Monovisc and Orthovisc, single- and multi-injection HA viscosupplements indicated for pain relief from OA, and Cingal, a non-opioid, single-injection product that combines cross-linked HA with a fast-acting steroid.
Monovisc: Single-injection HA viscosupplement for osteoarthritis pain, labeled for the knee in the U.S. Stage: Marketed.
Orthovisc: Multi-injection HA viscosupplement for osteoarthritis pain Stage: Marketed.
$112.8 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Anika Therapeutics, Inc. reported a net loss of $10.9 million for the fiscal year ended Dec 31, 2025, and generated $11.2 million of cash from operations, per its annual report to the SEC.
$25.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio